SK-N-BE(2)-C is a clonal subline of the SK-N-BE(2) neuroblastoma cell line. Like the parental cell line, these cells display MYCN amplification. Treatment with trans-retinoic acid differentiates these cells into a distinct neuronal phenotype. These cells display high levels of tyrosine hydroxylase activity and dopamine-b-hydroxylase activity.
This cell line is a subclone of the SK-N-BE(2) neuroblastoma cell line. The parental cell line was established in 1972 from a metastatic site (bone marrow) in a two-year-old Caucasian male with malignant neuroblastoma.
- June L. Biedler, PhD, former Chairman, Cell Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering
- Barbara A. Spengler, formerly at Sloan Kettering Institute, Memorial Sloan Kettering
- Ciccarone V et al. (1989) Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages. Cancer Research 49: 219-225 (PubMed ID: 2535691)
- Qiao J et al. (2012) PI3K/AKT and ERK regulate retinoic acid-induced neuroblastoma cellular differentiation. Biochemical and Biophysical Research Communications 424: 421-426 (PubMed ID: 22766505)
This cell line may be licensed nonexclusively for research or commercial purposes.
For internal research purposes by a commercial entity: Utilize MSK’s Express License, attached here. In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. Please note: This license is only available for select cell lines, including this one.
To proceed, please download this contract, fill in all relevant fields, and email a scanned version to TRMOTDRTM@mskcc.org. Once this license has been executed by MSK, you will receive a signed copy and invoice, and can then place your order with ATCC.
For licensing requests for a commercial purpose: Contact MSK’s Tangible Materials team at TRMOTDRTM@mskcc.org.
For non-licensing requests from academic-research institutions: Contact Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, email@example.com.